Glenmark Pharma hits 52-week high on double-digit FY25 earnings growth target

Glenmark Pharma expects double-digit profit growth in FY25.

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Shares of Glenmark Pharma soared 8.5 percent to hit a 52-week high of Rs 1,123.90 on May 27 as the management's upbeat growth guidance offset the drugmaker's weak quarterly performance.

After reporting weak earnings for the January-March quarter of FY24, the company's management stated that it is targeting double-digit profit growth and revenue growth of 10-11 percent for FY25.

In addition, the management also guided that its EBITDA margin will expand further to 19 percent in FY25. For context, the drugmaker's EBITDA margin stood at 16.5 percent in Q4 of FY24, up from 13.3 percent in the year-ago period.

At 1.35 pm, shares of Glenmark Pharma were trading at Rs 1,109.30 on the NSE.

Glenmark Pharma's net loss widened on year to Rs 1,238.6 crore for the March quarter from a net loss of Rs 549.4 crore in the same period a year ago.

Follow our live blog for all the market action

The company bore the brunt of an impairments of Rs 2,100 crore related to nebuliser/ oral solid dosage within the Monroe facility, Rs 1,100 crroe related to the de-prioritisation of certain intangibles of Glenmark Specialty and Rs 300 crore  related to the US Department of Justice Settlement, Anti-trust division settlement costs, and remediation costs of manufacturing sites in the US.

Glenmark's Monroe facility received a warning letter from the US Food and Drug Administration back in June 2023. The drugmaker also stated in its earnings call that it is in talks with the US drug regulator, requesting for a meeting and re-inspection of its Monroe facility.

The impairment charges also offset the Rs 5,140 crore from the stake sale in Glenmark Life Sciences.  Adjusting for these exceptional items in the quarter gone by, the drugmaker's net profit surged nearly 2.5 times to Rs 1,600 crore.

Revenue rose two percent to Rs 3,063 crore, up from Rs 3,000.5 crore in the same period a year ago.

Disclaimer: The views and investment tips expressed by investment experts on Moneycontrol.com are their own and not those of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.